益普生Ipsen（IPN）2025财年年度财报「巴黎泛欧证券交易所」（英文版）（36页）.pdf

1、FY 2025 results12 February 20262This presentation includes only summary information and does not purport to be comprehensive.Forward-looking statements,targets and estimates contained herein are forillustrative purposes only and are based on managements current views and assumptions.Such statements

2、involve known and unknown risks and uncertainties that maycause actual results,performance or events to differ materially from those anticipated in the summary information.Actual results may depart significantly from these targetsgiven the occurrence of certain risks and uncertainties,notably given

3、that a new medicine can appear to be promising at a preparatory stage of development or after clinicaltrials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons.Ipsen must deal with or may have todeal with competition from g

4、eneric medicines that may result in market-share losses,which could affect its level of growth in sales or profitability.The Company expresslydisclaims any obligation or undertaking to update or revise any forward-looking statements,targets or estimates contained in this presentation to reflect any

5、change inevents,conditions,assumptions or circumstances on which any such statements are based,unless so required by applicable law.All medicine names listed in this document are either licensed to Ipsen or are registered trademarks of Ipsen or its partners.The implementation of the strategy has to

6、be submitted to the relevant staff representation authorities in each country concerned,in compliance with the specificprocedures,terms and conditions set forth by each national legislation.In those countries in which public or private-health cover is provided,Ipsen is dependent on prices set for me